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Yacine Bareche1, Debora Fumagalli2, Dimitrios Zardavas2, Christine Desmedt1, Martine Piccart3, Sherene Loi12 and Christos Sotiriou1
Several studies have demonstrated the feasibility of molecular screening of tumour samples for matching patients with cancer to
targeted therapies. However, most of them have been carried out at institutional or national level. Herein, we report on the pilot
phase of AURORA (NCT02102165), a European multinational collaborative molecular screening initiative for advanced breast cancer
patients. Forty-one patients were prospectively enroled at four participating centres across Europe. Metastatic tumours were
biopsied and proﬁled using an Ion Torrent sequencing platform at a central facility. Sequencing results were obtained for 63% of
the patients in real-time with variable turnaround time stemming from delays between patient consent and biopsy. At least one
clinically actionable mutation was identiﬁed in 73% of patients. We used the Illumina sequencing technology for orthogonal
validation and achieved an average of 66% concordance of substitution calls per patient. Additionally, copy number aberrations
inferred from the Ion Torrent sequencing were compared to single nucleotide polymorphism arrays and found to be 59%
concordant on average. Although this study demonstrates that powerful next generation genomic techniques are logistically ready
for international molecular screening programs in routine clinical settings, technical challenges remain to be addressed in order to
ensure the accuracy and clinical utility of the genomic data.
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INTRODUCTION
Several efforts have advanced our understanding of the altera-
tions characterizing cancer genomes.1, 2 Coupled to recent
successes of targeted therapies in patients with molecularly
proﬁled tumours3, 4 and the decreasing costs of massively parallel
sequencing, this has motivated several studies, albeit of limited
size, to investigate the implementation of personalised molecular
screening in the clinical settings.5–7
Most of these studies were focused on primary tumours and
despite growing evidence that distant metastases may harbour
additional molecular alterations absent from their matched
primaries,8–12 genomic information about metastatic disease
remains limited. Even though the clinical relevance of many of
these alterations remains to be established, it is increasingly
recognised that molecular proﬁling of advanced disease could
help elucidate the biological underpinnings of phenomena such
as distant recurrence and the emergence of de novo resistance to
therapy.13 Lastly, in order to ﬁnd applications in routine clinical
practice, it is essential to assess the reliability and robustness of
the chosen sequencing platform using orthogonal sequencing
strategies.14, 15
The Breast International Group launched AURORA–Aiming to
Understand the Molecular Aberrations in Metastatic Breast Cancer,
a pan-European molecular screening programme whose main
goal is to deepen our knowledge of the genomic landscape of
advanced breast cancer.16 Herein, we report on the pilot phase of
this study whereby the primary objective was to investigate the
feasibility with four European recruitment sites and central
pathological and sequencing facilities. Secondary aims were to
assess the concordance of somatic mutations between two
targeted next generation sequencing (NGS) platforms and of
somatic copy number aberrations (CNA) obtained from NGS and
single nucleotide polymorphism (SNP) arrays.
RESULTS
Patient recruitment and logistics
A total of 41 patients provided informed consent and were
enroled in this pilot study between February 2013 and September
2014. Fig. 1a and b illustrates the study design and Table 1
summarises the clinical and pathological characteristics of the
patients. Formalin ﬁxed parafﬁn embedded (FFPE) biopsies of
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metastatic lesions and whole blood were prospectively collected
from 35 (85%) of them. 20 (57%) patients had ER +metastatic
disease, 7 (20%) were HER2 + and 8 (23%) were triple negative
breast cancer. Fig. 1c and d represent the distribution of the
different anatomical sites and the breakdown of patients’
recruitment by participating centre. Following central pathological
review, a tumour content below 10% was recorded for 8 (23%)
patients whilst the median cellularity was 50% (range 10–85). One
additional sample had an insufﬁcient amount of extracted DNA
whilst the median yield was 3.6 µg (range 0.075–59.2). Overall,
real-time Ion Torrent sequencing results were obtained for 26
(74%) of the 35 patients (Fig. 1b). The median global turnaround
time (TAT) from patient biopsy to sequencing results was 51
working days (range 16–146) whilst the median delivery TAT
from sample reception at the sequencing facility to ﬁnal NGS
report was 9 working days (range 5–17) (Fig. 1e). There were no
signiﬁcant differences in TAT between the recruiting centres
(Fig. 1f and g).
Mutation detection from the Ion Torrent OncoDEEP clinical cancer
panel and CNA using SNP arrays
Quality control metrics for the sequencing data are provided in
Supplementary Figure S1. The target regions were covered on
average at 1758X (494–3075X) sequencing depth. Non-
synonymous somatic mutations were called from the OncoDEEP
clinical cancer panel in exons covered by at least 100X sequencing
depth and a ﬁxed threshold of 10% variant allele fraction (VAF). In
total, 128 unique genes harboured at least one mutation
representing one third of the panel (Fig. 2a). The median number
of mutations indexed per patient was 6 (range 0–35) and the
overall mutation detection rate i.e., percentage of patients where
at least one mutation could be indexed, was 96%. Only 8 (4.15%)
of the 193 mutations had previously been described in release
v.76 of COSMIC in any type of cancer whilst 178 (92.23%)
mutations had never been reported in the literature. The most
frequently mutated genes were PIK3CA (50%), TP53 (31%), SYNE1
(19%), and NF2 (15%).
Fig. 1 Logistics and feasibility of the study. a logistic workﬂow of the study, b inclusion criteria and number of patients with successful results,
c anatomical distribution of biopsied lesions with breakdown by recruiting centre, d global distribution of patients by recruiting centre, e
turnaround time for each patient with breakdown by recruiting centre, f median global turnaround time by recruiting centre, and g median
delivery turnaround time by recruiting centre. In a, the Illumina sequencing and Affymetrix OncoScan SNP arrays were done as batch
processes. 19 patients were sequenced by Illumina targeted NGS and 18 patients were genotyped using the Affymetrix SNP arrays. However,
these are not fully overlapping subsets and only 14 (54%) patients had the full set of all three data types. In a and b, the Ion Torrent
sequencing results were obtained in real-time and in (e), the darker shades indicate delivery turnaround time (TAT) whilst the lighter shades
indicate global turnaround time. The colour codes for the recruiting centres in c to g are indicated in (d)
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We evaluated two established methods to call CNA from SNP
arrays and obtained similar results (Fig. 2c and d) thereby attesting
to the robustness of SNP arrays for the estimation of CNA. All the
patients presented with at least one CNA and the CNA frequencies
were comparable to those reported in the literature (Fig. 2d–g).
For instance, 13 (72%) patients harboured a gain or an
ampliﬁcation of chromosome 8q where the MYC oncogene
resides whilst 9 (50%) had a deletion of 17p where TP53 is located.
Two patients presented with a higher than expected number of
mutations. The integration of the sequencing and CNA data
obtained from these two outlier patients is shown in Supplemen-
tary Figure S2. In general, the distributions of VAF and cancer cell
fractions (CCF) were high and tightly clustered, indicative of
genuine somatic mutations. For the whole cohort, ERBB2
ampliﬁcation status was assessed centrally using FISH whilst PTEN
loss was evaluated by immunohistochemistry (IHC). These single
assay data were compared with CNA obtained from the SNP arrays
and the results are shown in Supplementary Figures S3 and S4. No
false negative calls were recorded for ERBB2 ampliﬁcation status
comparing SNP arrays to FISH data. However, 7 of 18 patients
(39%) effectively harboured supernumerary copies of ERBB2 (n≤ 4
copies) which were missed by FISH assays owing to centromere 17
co-ampliﬁcation or low level 17q polysomy. There was no concrete
evidence of a correspondence between PTEN IHC staining results
and the corresponding copy number level as determined by SNP
array.
Actionable alterations from targeted NGS and SNP arrays
Supplementary Tables S1 and S2 provide the deﬁnitions of
actionable and biologically relevant alterations. 19 of 26 (73%)
patients harboured at least one actionable mutation, such as
PIK3CAp.H1047R or ESR1p.Y537N, whilst 8 (31%) had only one
such mutation and six (23%) had at least one biologically relevant
mutation and none that were clinically actionable (Supplementary
Figure S5). Comparatively, 16 of 18 (89%) patients for whom the
SNP arrays were available harboured at least one actionable CNA,
such as EGFR ampliﬁcation,17, 18 whilst 2 (11%) had only one such
aberration and an equal number had at least one biologically
relevant CNA and none that were clinically actionable. Using the
combined information from the SNP arrays and the targeted
sequencing, and focusing on the subset of strictly actionable
alterations, 23 of 26 (88%) patients had at least one clinically
actionable alteration whilst only 3 (12%) had only one such
alteration. Overall, of the initial 7 patients without actionable
mutations, four were found to harbour at least one actionable
CNA.
Orthogonal cross-testing of substitution calls using Illumina NGS
The substitutions obtained from the Ion Torrent sequencing were
compared to data generated from the Illumina NGS platform. The
same DNA samples were sequenced and substitutions were called
in overlapping regions using similar ﬁltering criteria and a
combination of three established mutation callers. Patient
matched data were available for 19 (73%) patients and all three
mutation callers were mostly consistent (Fig. 3a). All but one
actionable substitution, NOTCH1p.D2082E in cluster 1 (see below),
were concordant.
The substitutions were categorised into three clusters and the
error rates of each mutation caller and several combinations
thereof were benchmarked using this framework. Substitutions in
clusters 1 and 3 are exclusive to one of the sequencing platforms
and have 0% VAF in the alternate data, whereas substitutions in
cluster 2 are those found by either or both NGS platforms and
have non-zero VAF in both sequencing data. The deﬁnite calls
were made for each substitution based on a majority vote of any
two of the three mutation callers (Fig. 3b and c). This choice was
guided by a low global Illumina speciﬁc false negative error rate
on cluster 2 substitutions whilst maintaining a relatively low global
Illumina speciﬁc false positive error rate on cluster 2 and 3
substitutions. Using this approach, a global concordance rate of
40.9% was achieved.
Substitutions in cluster 1 cannot be reconciled. There was a
statistically signiﬁcant difference in coverage between the Ion
Torrent and Illumina NGS data for these substitutions (Fig. 3d).
However, all but one of the substitutions were covered in excess
of 100X in the Illumina NGS data and the residual coverage, which
is the difference between the observed sequencing depth and the
expected value at 99% statistical power to detect a mutation for
given CCF and copy numbers, were positive for all except two
substitutions (Fig. 3e). Similarly, two substitutions were called in
cluster 3 which constitute Illumina speciﬁc false positives and were
covered at 239X and 1668X using the Ion Torrent NGS platform. In
total, only 2.7% of the substitutions in cluster 2 were Illumina
speciﬁc false positives using the Ion Torrent platform as standard
whilst 5.41% were Illumina speciﬁc false negatives. There were no
statistically signiﬁcant differences in sequencing coverage
between these groups of substitutions and the true positives
called by both platforms (Fig. 3f and g). Furthermore, similar to
cluster 1 substitutions, all the Illumina speciﬁc false negatives had
positive residual coverage (Fig. 3e). For comparison, the sequen-
cing coverage and the percentage of non-reference bases at these
particular loci in the normal matched samples are shown in
Supplementary Figure S6.
Comparison of CNA from targeted NGS and SNP arrays
The CNA obtained from the Ion Torrent sequencing were also
compared to the proﬁles obtained from SNP arrays and Illumina
Table 1. Clinical and pathological characteristics of patients and
biopsies (n= 35)
Characteristics Number of patients (%)
Age (years)
Median 56
Range 23–73
ECOG performance statusa
0 16 (45)
1 17 (49)
2 2 (6)
Breast cancer subtypea
ER+ 20 (57)
HER2+ 7 (20)
ER-/HER2- 8 (23)
Number of prior lines of therapy
0 6 (17)
1 5 (14)
2 4 (11)
3 6 (17)
>3 14 (41)
Number of metastatic sites
1 8 (23)
2 10 (28)
3 8 (23)
>3 9 (26)
a ECOG; Eastern Cooperative Oncology Group, ER; oestrogen receptor
evaluated by IHC, HER2; human epidermal growth factor receptor 2
evaluated by IHC and FISH. The breast cancer subtypes are based on the
characteristics of the metastatic lesions
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NGS. Fig. 4a–c show the Log2 ratios from the SNP array and both
NGS platforms for a case patient. The segmented Log2 ratios from
the SNP array and Illumina sequencing clustered, as expected, into
canonical copy number genotypes whilst the segmented Log2
ratios obtained from the Ion Torrent NGS platform were spread
between those canonical genotypes leading to relatively poor
correlation in Log2 ratio data space (Fig. 4d and e). Nonetheless,
this approach was applied to each copy number platform for 14
(54%) patients for whom all three data types were available and
the segmented Log2 ratios were compared genome-wide using
the Spearman’s correlation. The distribution of correlation
coefﬁcients comparing the SNP array to the NGS data was
bimodal for the Ion Torrent platform with 5 (29%) samples
displaying a poor correlation of ρ < 0.5 (Fig. 5a). The median
correlation coefﬁcients were ρ = 0.615 and ρ = 0.745 for the Ion
Torrent and Illumina NGS platforms respectively.
In order to further evaluate the ability of both NGS platforms to
call CNA, the segmented Log2 ratios were grouped into three
categories i.e. deletion (−1), copy neutral (0), gain/ampliﬁcation (1)
and further compared using the accuracy which is the sum of
concordant calls relative to the total number of aberrations. Fig. 5b
shows the distribution of accuracy values evaluated genome-wide
for each patient. The average accuracy of CNA call was 59.1% for
the Ion Torrent and 74.0% for the Illumina NGS platforms. Both
Fig. 2 Mutation detection from the OncoDEEP clinical cancer panel and CNA from SNP arrays. a genes for which at least one mutation was
indexed across the 26 patients, b and c comparison of cancer cell fraction and genomic mass respectively obtained from two widely used
algorithms for estimating CNA from SNP arrays. In a, asterisk indicates potentially hypermutated patients. In b and c, each dot represents a
sample. In d–g, each dot represents a gene from the list of clinically actionable or biologically relevant targets and is the mean of 100
bootstrap replicates such that for each replicate, the external cohorts are matched for ER and HER2 status. The size of each dot is proportional
to the standard error of the mean frequency estimate
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distributions were bimodal with 6 (35%) and 5 (29%) patients
showing low values of α < 0.5 and α < 0.6 for the Ion Torrent and
Illumina NGS platforms, respectively. Lastly, the ability of both
sequencing platforms to call CNA in particular genes of interest
was evaluated on 15 clinically actionable or biologically relevant
genes. For each gene, the CNA calls were pooled and the cohort-
wise concordance measured as the accuracy of concordant calls.
Fig. 5c contrasts the distribution of accuracy values observed
across these 15 genes for both NGS platforms. We observed
relatively high concordance rates using the Illumina NGS platform
for genes frequently aberrant in breast cancers e.g., 90.1% (95% CI:
86.8–93.3) for MYC, 63.8% (95% CI: 61.4–66.2) for CCND1 and
57.4% (95% CI: 52.3–62.5) for ERBB2 whilst the corresponding
values for the same genes were 29.5% (95% CI: 27.5–31.8), 40.2%
(95% CI: 37.7–42.7) and 28.3% (95% CI: 25.6–30.9), respectively,
using the Ion Torrent sequencing platform. There was a signiﬁcant
negative correlation between the accuracy and the number of
aberrations per patient for the Ion Torrent data (Fig. 5d) but not
for the Illumina NGS platform (Fig. 5e). There were no associations
between the accuracy measured cohort-wise and the frequency of
aberrations affecting the 15 genes of interest for either of the two
NGS platforms (Fig. 5f and g).
Fig. 3 Orthogonal cross-testing of substitution calls using Illumina NGS. a distribution of % concordance for single nucleotide substitutions
indexed from the Ion Torrent and Illumina NGS platforms using different mutation callers, b % error rate of the different mutation callers over
three substitution clusters compared to the Ion Torrent sequencing, c correlation of VAF for substitutions indexed from the Ion Torrent and
Illumina NGS using a majority rule of any two of three mutation callers, d comparison of sequencing coverage between the Ion Torrent and
Illumina NGS for substitutions in cluster 1, e empirical cumulative distribution of theoretical residual coverage from the Illumina sequencing
for substitutions in cluster 1 and cluster 2 false negatives, f comparison of sequencing coverage from the Ion Torrent NGS for substitutions in
cluster 2 false positives, and g comparison of sequencing coverage from the Illumina NGS for substitutions in cluster 2 false negatives. In a, the
different mutation callers and any combination thereof are colour coded and indicated at the bottom. The leftmost panel gives the number of
substitutions called. In b–g, the cluster numbers are relative to (c). Substitutions in clusters 1 and 3 are exclusive to one of the sequencing
platforms and have 0% VAF in the alternate data. Substitutions in cluster 2 are those found by either or both NGS platforms and have non-zero
VAF in both sequencing data. False negatives in cluster 2 are substitutions indexed by Ion Torrent NGS only whilst false positives are
substitutions indexed by Illumina NGS only using a given mutation caller or any combination thereof. The size of each dots is proportional to
the difference in coverage between the two sequencing platforms. In e, the residual coverage is obtained by subtracting the theoretical
coverage required to achieve 99% power for indexing a substitution given one mutated copy out of n total copies from the observed value of
sequencing depth. Only two substitutions in cluster 1 failed the criteria of positive residual for detection and are non-callable loci
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DISCUSSION
The growing number of targeted anticancer therapies either
approved or under clinical development has led to a wide interest
in personalised treatment approaches in clinical practice.19, 20
However, many of these cancer molecular screening initiatives
have had limitations. For instance, several of these screening
programs used different sequencing techniques and very often
lacked orthogonal validation. Together with varying concepts of
what constitutes an actionable mutation, this makes the results
difﬁcult to compare. The current study is a pilot phase undertaken
to evaluate the feasibility of AURORA, a pan-European molecular
screening programme for advanced breast cancer patients.
The success rate for the primary endpoint of 63% compares
favourably with existing literature.5–7, 21 The median global TAT of
51 working days was due to unforeseen delays either between
patient consent and surgical biopsy or between collection of
biological samples and shipment to the central pathology
laboratory. In part, due to the above ﬁndings, these parameters
are now rigorously monitored in the parent programme where the
global TAT does not exceed 20 working days (personal
communication). 73% of the patients harboured one or more
actionable mutations and this increased to 88% when considering
the underlying CNA. These numbers are encouraging on account
of the availability of alterations that can be theoretically targeted
despite limited clinical trial based evidence of beneﬁt to patient
survival from targeted therapy in breast cancer. Yet, the decision
to prioritise a particular molecular target for trial allocation given
several such alterations within the same patient constitutes a
considerable challenge for which speciﬁc algorithms and com-
bined expertise will be required in the future.
Regarding the secondary endpoint and considering clinically
actionable mutations, our results are reassuring. All but one
substitution was positive using both the Ion Torrent and Illumina
sequencing platforms. Furthermore, from a pragmatic viewpoint, 5
(26%) sample pairs showed complete agreement. However, no
single mutation caller was able to reproduce globally with 100%
concordance the results obtained in real-time from the Ion Torrent
NGS platform. The Illumina speciﬁc false negative and false
positive rates over somatic substitutions with non-zero VAF in
both data types can be reasonably contained whilst substitutions
Fig. 4 Genome-wide copy number proﬁles inferred from SNP arrays and targeted NGS data. Genome-wide Log2 ratio proﬁles of patient
IJB0021 obtained using a SNP array b Ion Torrent and c Illumina targeted NGS data. The solid vertical lines represent chromosome boundaries
whilst the dashed horizontal lines indicate canonical copy numbers inferred from the cancer cell fraction and ploidy of the sample, both
estimated from the SNP array. The solid horizontal lines represent the segmented Log2 ratios. Correlation of segmented Log2 ratios between d
the SNP array and the Ion Torrent platform, e the SNP arrays and the Illumina platform, and f the two NGS platforms for the same case patient.
In a–c, the loci are sorted according to their coordinate on the human genome reference hg19/GRCh37. For ease of representation, they are
plotted by indices
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private to either sequencing technology despite adequate cover-
age in both data types were more frequent in the Ion Torrent data.
Thus, from a technical perspective, our results are somewhat
sobering and whilst the higher background error rate of the Ion
Torrent NGS technology could be a contributing factor, the small
number of samples and mutations assessed here do not allow for
a full exploration of the possible causes of these discrepancies.
Massively parallel sequencing using targeted gene panels has
emerged as a technology that can be applied within a clinically
meaningful TAT to identify known biomarkers of resistance or
sensitivity to a given drug. In the broader context of AURORA, all
the results are reported to investigators unaltered. However, our
analysis shows the major limitations of this approach outside
known mutation hotspots and in anticipation, the AURORA study
design allows biobanking of frozen and residual FFPE material for
later research purposes using alternative high-throughput tech-
nologies such as whole genome or exome sequencing.
To the best of our knowledge, no other studies have compared
prospectively CNA obtained from targeted sequencing data to
SNP arrays in a clinical setting. Our results show that the gold
Fig. 5 Comparison of copy number proﬁles from SNP arrays and targeted sequencing data. a distribution of Spearman’s correlation coefﬁcient
comparing the segmented Log2 ratios from the SNP arrays and the NGS data across patients with all three data types. The segmented Log2
ratios were further categorised into copy number aberration calls i.e., −1, 0 and +1 and compared patient wise between the SNP arrays and
the NGS data. The resulting distributions of accuracy values are depicted in b. For a small set of 15 clinically actionable or biologically relevant
genes, the accuracy values comparing SNP arrays and NGS data were computed using all available samples and displayed individually for each
gene in c. d, e correlation of accuracy values measured genome-wide for each patient as in b vs. the number of aberrations as determined by
the corresponding NGS platform. f, g correlation of accuracy for each of the 15 clinically actionable or biologically relevant genes vs. the
frequency of aberrations for the same genes measured using the SNP array. In c, each value of accuracy was generated by 100 bootstrap
replicates. The values displayed represent the mean of the replicates and the error bars represent the standard error of this estimate
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standard FISH assay for ERBB2 is fully concordant with SNP arrays.
However, the Illumina NGS platform outperforms the Ion Torrent
technology when compared to the same SNP arrays. This is not
unexpected since the Illumina NGS panel accommodates inter-
genic targets which, combined with the fact that hybrid capture
methods for sequencing library preparation often carry over off-
target reads, increases the effective number of regions where
copy numbers can be evaluated. Several algorithms22, 23 take
advantage of this, beneﬁting downstream CNA calling and
translating into higher concordance with the denser SNP arrays.
The combination of assays, such as mutation proﬁling and
assessment of CNA, into one cost effective package is an attractive
idea. Together with a low requirement of input DNA, as is often
obtainable from clinical samples, makes for a compelling
argument in favour of the Ion Torrent NGS platform. However,
given the poor agreement with solid benchmarks such as SNP
arrays, the results presented here do not support, at least for now,
the targeted Ion Torrent NGS platform as a truly multipurpose
assay in a clinical setting. Within AURORA, central pathology
results reported to investigators in real-time include ERBB2 IHC as
well as FISH when applicable. This is clinically meaningful since
ERBB2 gene ampliﬁcation remains, to date, the sole approved CNA
biomarker in breast cancer. Sub-studies undertaken in the
framework of the main AURORA programme include real-time
SNP arrays and retrospective whole genome sequencing to
alleviate the technical limitations of identifying CNA using the
Ion Torrent technology and will allow the study of the clonal
evolution of breast cancer.
Overall, our study contrasts the beneﬁts and pitfalls of
personalised molecular screening for patients with advanced
cancer involving the combination of multiple high-throughput
genomic techniques. In view of these results, greater effort is
being devoted to improving the concordance of mutation calls
between different NGS platforms and to harmonising CNA calls
with SNP arrays in the ongoing AURORA programme. With recent
ﬁndings on the clinical utility of circulating tumour DNA11, 24 and
its implementation into the AURORA study design, it becomes
imperative to thoroughly evaluate the technical feasibility of
proﬁling circulating biomarkers to support clinical decision
making.
METHODS
Patients and samples
Patients were enroled in four European centres (Institut Jules Bordet,
Belgium; Hospital Vall d’Hebron, Spain; Sana Klinikum Offenbach, Germany;
and Dundee Cancer Centre, United Kingdom). The study was approved by
the respective ethical committees from the named institutions and was
performed in accordance with relevant guidelines and procedures. Patients
considered eligible for this study were those (1) with histologically proven
distant metastatic or locally recurrent invasive breast cancer (2) with an
Eastern Cooperative Oncology Group Performance Status equal to or less
than two, (3) with clinical and laboratory parameters safe for tumour
biopsy, (4) for whom FFPE tumour tissue from a locally recurrent or
metastatic lesion and whole blood for research purposes were available.
The samples were centralised in real time at the European Institute of
Oncology (Milan, Italy) where H&E slides were reviewed by a board-
certiﬁed pathologist for the evaluation of cellularity. At the central
laboratory, IHC for ER, PR, HER2, Ki67 and PTEN were performed using the
ER pharmDx kit (Dako), the HercepTest kit (Dako), the mouse mAb anti h-
Ki-67, the clone MIB-1 (Dako) and the rabbit mAb anti h-PTEN, clone 138G6
(Cell Signalling) respectively. FISH for ERBB2 was performed using the HER2
FISH pharmDx kit (Dako) and scored according to the ASCO/CAP
guidelines. Wherever applicable, macrodissections to enrich for tumour
cells were performed. DNA was extracted from the tissue and blood
samples using either the Qiagen DNA FFPE tissue kit and the QIAamp
DNeasy blood and tissue kit, respectively, following the manufacturer’s
instructions. The cut-off values for tumour content and DNA quantity were
10% and 400 ng, respectively. DNA concentrations were measured using
the Qubit ﬂuorometer (Life Technologies) following which, aliquots were
shipped to (1) OncoDNA (Gosselies, Belgium) for sequencing using Ion
Torrent NGS technology, (2) the Wellcome Trust Sanger Institute (Hinxton,
UK) for sequencing using Illumina NGS technology, and (3) the J.-C. Heuson
Breast Cancer Translational Research Laboratory (Brussels, Belgium) where
the Affymetrix OncoScan FFPE Express arrays were performed. The Illumina
NGS and Affymetrix SNP arrays were performed as batch processes whilst
the sequencing and delivery of results from OncoDNA were monitored in
real time.
Targeted gene screen using Ion Torrent NGS
Somatic mutations were assessed using the OncoDEEP clinical cancer
panel which is a validated AmpliSeq design panel targeting the exonic
regions of 409 cancer related genes (Supplementary Table S3). The same
protocol was applied to DNA extracted from FFPE tumour and whole blood
normal matched samples. Brieﬂy, the targeted sequencing libraries were
generated using the Ion AmpliSeq library kit 2.0 according to the
manufacturer’s instructions (Life Technologies) using 80 ng of genomic
DNA. The primers used for ampliﬁcation were partially digested by Pfu
restriction enzyme and the digestion products were ligated to barcoded
adaptors and puriﬁed using Ampure Beads. The puriﬁed products were
ampliﬁed for ﬁve cycles and puriﬁed once more using Ampure Beads. The
quality of the libraries was assessed using a qPCR following which 10 pM of
each library underwent emulsion PCR using an IonChef system. The chips
were loaded on an Ion PGM and were sequenced at a target coverage of
500X.
Targeted gene screen using Illumina NGS
The exonic regions of 371 cancer related genes (Supplementary Table S4)
were enriched using a custom design of SureSelect RNA baits following the
manufacturer’s instructions (Agilent). The same protocol was applied to
DNA extracted from tumour and normal matched samples. Brieﬂy, 500 ng
of genomic DNA was fragmented to an average insert size of 145 bp
(75–300 bp) and subjected to Illumina DNA sequencing library preparation
using the Bravo automated liquid handling platform. Individual samples
were indexed using a unique DNA barcode via six cycles of PCR. Equimolar
pools of 16 libraries were prepared and hybridised to the custom RNA baits
and sequenced using an Illumina HiSeq device in 75 bp paired-end mode
at a target coverage of 200X.
Copy number aberration proﬁling using SNP arrays
Copy number aberration proﬁling using the SNP arrays was performed
according to the manufacturer’s instructions (Affymetrix). In short, the
molecular inversion probes (MIP) were incubated with the FFPE extracted
DNA at 58°C overnight after an initial denaturation at 95°C for 5 min. Each
sample was then split into two aliquots and a gap ﬁll reaction was
performed. Uncircularised MIP and genomic DNA were digested using a
cocktail of exonucleases. The remaining circular MIP were then linearised
using a cleavage enzyme and ampliﬁed by PCR. Following a second round
of PCR ampliﬁcation, the 120 bp amplicons were cleaved into two
fragments with the HaeIII enzyme. The samples were then mixed with
the hybridisation buffer and injected into the arrays where they were
allowed to hybridise at 49°C for 16–18 h. At the end of the hybridisation
period, the arrays were stained and washed using the GeneChip Fluidics
Station 450 and loaded into the GeneChip Scanner 3000 where array
ﬂuorescence intensity was scanned to generate binary CEL ﬁles using the
Affymetrix GeneChip Command Console.
Bioinformatics analyses
Mutation calling from Ion Torrent targeted gene screen. Sequence reads
from the tumour and matched normal samples were aligned against the
human genome reference version hg19/GRCh37 using the Ion Torrent
TMAP aligner with default parameter settings. Mutations were called from
the resulting BAM ﬁles using the Torrent Suite variant caller (Life
Technologies) with the default settings of the ‘Somatic High Stringency’
pipeline and cross-checked using the NextGENe software (Softgenetics)
using the ‘Ion Torrent’ predeﬁned pipeline. Germline mutations were
ﬁltered by subtracting variants found in the matched normal sample from
those called in the corresponding tumour sample. The resulting somatic
mutation calls were further ﬁltered to exclude variants (1) that were not
sequenced in both sense with a minimum ratio of 10/90%, (2) with less
than 100 read depth, and (3) variant allele fractions lower than 10% in the
tumour sample. For an alpha list of target genes (Supplementary Table S5),
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mutations occurring below 10% VAF were accepted. Manual evaluation
was done for indels using IGV.25
Mutation calling from Illumina targeted gene screen. Sequence reads from
the tumour and matched normal samples were pre-processed according to
the GATK best practices. The raw reads were aligned against the human
genome reference hg19/GRCh37 using the BWA aligner.26 Duplicate reads
were marked using Picard following which the data were ﬁltered to keep
only properly paired and mapped reads with mapping quality greater than
60. Sequence reads around potential indels were locally realigned and the
base quality scores were recalibrated using GATK.27 Mutations were called
from the resulting BAM ﬁles using MuTect2,28 SomaticSniper29 and
Strelka30 in matched tumour/normal mode using the default parameter
settings for each of the aforementioned algorithms. The resulting somatic
mutation calls were further ﬁltered to include only variants (1) occurring in
regions common to both Ion Torrent and Illumina sequencing panels, (2)
having a VAF above 10% in the tumour sample, and (3) having a read
depth greater than 50X. Similar to the Ion Torrent NGS, mutations
occurring in the alpha list (Supplementary Table S5) were accepted if they
occurred with a VAF below 10%. The resulting lists of mutation calls were
considered individually for each mutation caller or combined by voting
using (1) a simple rule of a mutation indexed by at least one of the three,
(2) a majority rule of a mutation called by at least two of the three, and (3)
a strict consensus of all three mutation callers. In downstream comparison,
we considered only substitutions on account of the known issues of calling
indels with conﬁdence from Ion Torrent NGS data.
Copy number aberration analysis using SNP arrays. The raw intensity
values were normalised to obtained Log2 ratios, B Allele Frequencies (BAF)
and genotyping calls (AA/AB/BB) using Affymetrix Power Tools. We used
release NA.33 of the NetAffx library for the reference model and
annotation. We computed the Median Absolute Pairwise Deviation and
the Median Auto-Correlation from the Log2 ratios as quality control metrics
and used a threshold of 0.40 and 0.45, respectively, to discard failed arrays.
We used two parallel approaches involving (a) allele speciﬁc copy number
analysis using heterozygous SNP probes and (b) total copy number
analysis using the full set of 200 K markers and parameters from (a) to
control for the cancer cell fraction and genomic mass. From the BAF and
genotyping calls, only informative SNP probes displaying heterozygous
genotype (AB) and 0.1 < BAF < 0.9 were kept for analysis at (a). The Log2
ratios and BAF were smoothed using the median absolute deviation and
segmented jointly using a multitrack segmentation algorithm from the
library copynumber31 to determine common breakpoints. Estimates for the
cancer cell fraction and genomic mass were obtained using GAP32 and
compared to the results obtained from ABSOLUTE33. Samples with a cancer
cell fraction lower than 30% were further excluded. For analysis at (b), the
Log2 ratios for the same samples analysed at (a) were segmented by
penalised least square regression as above and non-rounded estimates of
copy numbers were obtained as
y ¼ 1
α
2
x
c ψαþ 2 1 αð Þð Þ  2 1 αð Þ 
where α is the CCF and ψ is the genomic mass, both estimated at (a). c =
0.8 is a constant representing the compression ratio of the array and ﬁnally
x is the observed Log2 ratio of a given segment. The copy numbers were
categorised as deletions (−1) if y < ψ−0.5, gains (+1) if y > ψ + 0.5,
ampliﬁcations (+2) if y > ψ + 2.5, and copy neutral (0) otherwise. Unless
otherwise stated, all parameter settings were kept at default values and all
computations were done using R/Bioconductor.
Copy number aberration analysis using targeted NGS. The read counts
from aligned and sorted BAM ﬁles of the Ion Torrent sequencing were
processed using ONCOCNV34 with default parameter settings to correct for
library size, GC content and amplicon length. The pool of normal samples
was used as baseline control to capture the technology speciﬁc bias
against which each tumour sample was normalised to obtain an estimate
of Log2 ratio. The Log2 ratios were segmented using the circular binary
segmentation35 and CNA calls were obtained using the default clustering
approached implemented in ONCOCNV. The read counts from the aligned
and sorted BAM ﬁles of the Illumina sequencing were processed using
cnvkit22 to obtain an estimate of Log2 ratio for on and off target regions.
The pool of normal samples was used as baseline control against which
each tumour sample was normalised. The Log2 ratios were smoothed by
median absolute deviation and segmented by penalised least square
regression using the library copynumber.31 Estimates of cancer cell fraction
and genomic mass were obtained using ABSOLUTE33 and non-rounded
estimates of copy numbers and copy number calls were obtained as
described above for SNP arrays. Unless otherwise stated, all parameter
settings were kept at default values.
Statistical analyses
Integration of the VAF of mutations indexed by the Ion Torrent NGS
platform and CNA proﬁles from the matched SNP arrays to compute the
Log-Likelihood and individual CCF of each mutation was done using
ABSOLUTE.33 Similarly, the sequencing depth required to achieved 99%
statistical power to call a given base was computed using ABSOLUTE33
with an error rate E = 2E-03 and an FDR = 5E-07. The frequencies of
aberration calls and the percentage accuracy were obtained by boot-
strapping. The values displayed are mean estimates and conﬁdence
intervals are standard errors. The concordance of mutation calls for
substitutions was evaluated using the simple matching coefﬁcient. All
correlations were measured using the non-parametric Spearman’s ρ
coefﬁcient and all statistical hypothesis tests were done using the non-
parametric Wilcoxon’s rank sum test. P-values were two sided and paired
or unpaired as appropriate. Unless otherwise stated, all computations were
done in R/Bionconductor.
Data availability
The sequencing and SNP arrays data have been deposited at the European
Genome-Phenome Archive (http://www.ebi.ac.uk/ega/) which is hosted by
the European Bioinformatics Institute, under accession number
EGAD00001000870.
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